- Big Bank Phobia: Not Too Big to Fail
- Expect Your Health Care in Retirement to Hit $200,000
- Why Car Prices Vary From City To City
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
- 5 Worst Home Renovation Projects

Oncothyreon: A Failed Drug Autopsy Performed By A Short Seller
Fund manager Martin Shkreli offers advice on how to avoid the next Oncothyreon blowup.
10:10AM 12/19/12

Nektar Therapeutics Is a Short
Investor Martin Shkreli believes Nektar's constipation drug is a bust and the stock is a good short.
07:08AM 09/12/12